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TCT-798
Long-term Follow-up of Mitral Valvuloplasty with Single Balloon. Independent
Predictors of Survival and Event Free Survival
Edison S Peixoto2, 3, Ricardo S Peixoto1, 2, Rodrigo S Peixoto2, Ivana P Borges2,
Paulo S Oliveira2, Aristarco G Siqueira-Filho1
1Rio de Janeiro Federal University, Rio de Janeiro, Brazil; 2Cinecor Evangelico
Hospital, Rio de Janeiro, Brazil; 3Fluminense Federal University, Niteroi, Brazil
Background: Mitral balloon valvuloplasty (MBV) with single balloon MBVSB) is
the less expensive technique to perform MBV with similar outcome and long-term
follow-up (FU) when compared with Inoue balloon technique
Methods: From 1987 to 2010, 526 procedures of MBV was performed, 404 (77.1%)
with MBVSB Balt, being 256 with long-term FU. Mean dilatation area was 7.02±0.30
cm2 and the FU 54.6±32.8 months. To determine independent predictors of survival
and event free survival (EFS) it was used the multivariate Cox analysis.
Results: Mean age was 38.0±12.6 years, being 222 (86.7%) female, 215 (84.0%)
patients in sinus rhythm and echo score 7.2± 1.5 points. Mean pre and post-MVA
(Gorlin) were 0.90±0.20 and 2.02±0.37 cm2 (p<0.001) and we had success MVA ≥1,5
cm2 in 241 (94.1%) procedures. Three (1.2%) patients began the FU with severe mitral
regurgitation (MR). At the end of the FU 119 (46.5%) patients were in NYHA FC I,
70 (27.3%) in FC II, 53 (20.7%) in FC III, 3 (1.2%) in FC IV and there were 11 deaths
(4.3%). There were 17 (8.2%) patients with new severe MR at the end of the FU, twelve
(4.7%) were submitted to new MBV, 27 (10.5%) to mitral valve surgery and 70 (26.3%)
used no medication at the end of the FU. Independent predictors of survival were: echo
score ≤8 (p<0.001, HR=0.116, 95% IC 0.035-0.384), age ≤ 50 years old (p=0.011, HR
0.203, 95% IC 0.059-0.693) and absence of mitral surgery in the evolution (p=0.004,
HR 0.170, 95% IC 0.050-0.571) in multivariate analysis with 6 or 7 variables.
Independent predictors of EFS were: absence of prior comissurotomy (p<0.002, HR
0.318, 95% IC 0.151-0.667), female gender (p=0.036, HR 0.466, 95% IC 0.229-0.951)
and MVA post MBV ≥ 1.50 cm2 (p<0.001, HR 0.466, 95% IC 4.884-28.457) in
multivariate analysis.
Conclusion: MBVSB Balt was efficient with durable results similar to other
techniques. Independents predictors of survival were: echo score ≤8, age ≤ 50 years
old and absence of mitral surgery in the evolution. Independent predictors of EFS were:
absence of prior comissurotomy, female gender and MVA post MBV ≥1.50 cm2.
TCT-799
Functional vs. Degenerative Mitral Regurgitation in Patients not Amenable to
Surgery Undergoing MitraClip Treatment
Stephan Baldus1, Volker Rudolph1, Michael Schlueter1, Olaf Franzen2, 1, Malgorzata
Knap1, Hendrik Treede1, Hermann Reichenspurner1, Stefan Blankenberg1
1University Heart Center, Hamburg, Germany; 2Rigshospitalet, Copenhagen,
Denmark
Background: Transcatheter MitraClip (MC; Abbott Vascular, IL) implantation is a
viable therapeutic option in patients (pts) with both degenerative (DMR) and functional
mitral regurgitation (FMR). The impact of MR etiology on acute and mid-term
outcomes of MC therapy has not been sufficiently elucidated.
Methods: Of 104 consecutive MC pts (all in NYHA III/IV; 103 with MR 3+/4+; 74 ±
9 years; 64 men) adjudicated not amenable to surgery, 69 pts (66%) had FMR and 35
pts had DMR. The latter tended to be older (mean 76 vs. 73 years, p=0.09), had less
often cardiomyopathy, significantly lower LV dimensions, and significantly better LV
function (mean EF 56% vs. 37%, p<0.0001). Follow-up was assessed at 1 year
(median) post-MC.
Results: Device success (MR ≤2+) was achieved in 30 DMR (86%) and 66 FMR pts
(96%, p=0.12); in successfully treated pts, DMR tended to require more often multiple
clips (50% vs. 29%, p=0.06). Clinical follow-up (FU) at 1 year was obtained from 24
DMR (80%) and 57 FMR pts (86%), echocardiographic FU from 19 DMR (63%) and
44 FMR pts (64%). Improvement in NYHA class was observed in 22/24 DMR pts
(92%) and 43/57 FMR pts (75%, p=0.13). Six-minute walk distance improved in 14/16
DMR pts (88%) and 27/39 FMR pts (69%, p=0.19) by 172 and 105m, respectively
(p=0.34). Improvement in Minnesota QoL score (-18 points in both groups) was
reported by 10/10 DMR pts (100%) and 25/37 FMR pts (68%, p=0.046). MR grade at
FU was improved in 18/19 DMR pts (95%) and 39/44 FMR pts (89%, p=0.66), with
MR 1+/2+ in 17 (90%) DMR and 35 (80%, p=0.48) FMR pts. Significant median
reductions in LV end-diastolic volume were present in both groups (DMR: -33ml,
p=0.003; FMR: -28ml, p<0.0001), as were significant median increases in forward
stroke volume (DMR: 7ml, p=0.04; FMR: 6ml, p=0.0005). One-year estimates of
survival free from death, rehospitalization or reintervention were 54.1% in DMR and
48.8% in FMR pts (p=0.91).
Conclusion: Despite a tendency toward lower device success in DMR pts, MC therapy
in pts not amenable to surgery appears to be clinically efficacious at 1 year regardless
of MR etiology.
TCT-800
Quality Of Life Changes In High Risk Patients after Percutaneous Mitral Valve
Repair with Mitraclip
Maurizio Taramasso, Paolo Denti, Micaela Cioni, Nicola Buzzatti, Antonio
Colombo, Ottavio Alfieri, Francesco Maisano
Cardiac Surgery, San Raffaele Scientific Institute, Milan, Italy
Background: Percutaneous mitral valve repair with the Mitraclip System is a
therapeutic option for selected patients with severe symptomatic mitral regurgitation
(MR). The aim of the study was to investigate the changes of QoL following Mitraclip
implantation in a series of consecutive high risk patients.
Methods: From October 2008 to April 2011, 76 consecutive patients with severe MR
underwent Mitraclip implantation at our Institution (32% degenerative; 68% functional;
mean age 71,3±11,4 years). Mean Log-EuroScore was 20,6±13,3% (18,3±9,2% for
degenerative; 21,6±24,7% for functional). Mean LVEF was 60,2±6,9 for degenerative
and 27,7±10,0 for functional. All patients underwent a standardized prospective
screening pathway, including QoL evaluation with the Short-Form Health Survey 36-
Item (SF-36v2®) and the Minnesota Living with Heart Failure Questionnaires
(MLHFQ). The scores obtained preoperatively were compared with those obtained at
latest follow-up.
Results: Procedural success rate was 97,4% (2/76 conversion to surgery due to leaflet
rupture). In-hospital mortality was 1,3% (1 patient converted to surgery died from
mediastinitis). Follow up was 100% complete (median 178 days; IQR 78,3-346,5 days).
Actuarial 1,5 years survival was 89,8±6,1% (95,6±4,3% for degenerative; 89,1±7,2%
for functional -p=0,06). At last follow-up, 84,2% of the patients had MR≤2+. A
significant improvement of LVEF was observed in the functional MR group (from
28,3±10% to 35,5±10,1%, p<0,0001). Mean SF36-physical improved from 35,2±9,1
to 43,2±9,0 (p<0,003) and SF36-mental improved from 42,0±8,7 to 49,4±7,1
(p=0,003). MLHFQ decreased from 36,3±13,9 to 18,4±16,4 (p<0,0001). QoL changes
were not influenced by age, comorbidities and MR etiology.
Conclusion: Mitraclip repair in selected high risk patients is associated with excellent
short and long term mortality and with substantial improvement of QoL, regardless of
age, comorbidities and MR etiology.
TCT-801
The Impact of Commissural Morphology on Clinical Outcome in Patients
Undergoing Percutaneous Balloon Mitral Valvuloplasty
Mohamed Ahmed Sadaka, Eman Elsharkawy, Magdy Rashwan, Rasha Abdo
cardiovascular, Alexandria University, Alexandria, Egypt
Background: Commissural morphology has a prognostic value on the immediate and
short term outcome after Percutaneous balloon mitral valvuloplasty despite of the low
Wilkin’s echocardiographic score.
Methods: The study included 30 patients with symptomatic mitral stenosis scheduled
for percutaneous balloon mitral valvuloplasty using multitrack system for 30 patients,
they were randomized prospectively into 2 groups: Group (1): 12 patients with only 1
mitral commissure was opened after the procedure. Group (2): 18 patients with both
mitral commissures were opened after the procedure
Results: Immediate follow up: no patient developed atrial fibrillation, embolization
or severe degree of regurgitation . The mean mitral valve area increased from 0.94±0.19
cm2 to 1.86± 0.27 cm2 in group 1 & from 0.91±0.18 to 2.29±0.33 cm2 in group 2
(p=0.001). The mean transmitral gradient decreased from 21.83+4.1 to 8.08±2.9mmHg
in group (1) and from 18.28±5 mmHg to 5.2±1.76 mmHg in group 2 (p=0.003). Three
months follow up: During follow up no recorded cases of death, hospital admission,
redo, or surgery &most of them in NYHA functional class 1-2. The mitral valve area
ranged between (1.6-2.1) with mean 1.8 cm2 in group 1 and ranged between (1.8-3.1)
with mean 2.2 cm2 in group 2 (p=0.001). The mean Transmitral gradient ranged
between (3-12) with mean 8.08 mmHg in group 1 and ranged between (3-9) with mean
5.47 mmHg in group 2 (p=0.001).
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